AstraZeneca: 59% Of Patients Treated With Tagrisso + Chemotherapy Had Complete Brain Tumor Responses
21/10 16:59
(RTTNews) - AstraZeneca (AZN.L, AZN) said that results from a prespecified exploratory analysis of the FLAURA2 Phase III trial showed the company's Tagrisso(osimertinib) with the addition of chemotherapy demonstrated a 42% improvement in central nervous system (CNS) progression-f...